Nervgen Pharma Corp Stock Price, News & Analysis

NervGen Pharma (OTCQB:NGENF) intends to amend 5,075,000 common share purchase warrants issued July 13, 2022. The proposed amendment converts the exercise price denomination from US$1.75 to the Canadian equivalent of C$2.44 to align with the company's functional currency and simplify accounting.

All other warrant terms remain unchanged. The amended terms are subject to acceptance by the TSX Venture Exchange.

NervGen Pharma (OTCQB:NGENF) reported third-quarter 2025 results and business updates highlighting expanded CONNECT SCI Study data, regulatory engagement, financing and pipeline progress. Expanded data showed durable, clinically meaningful improvements at Week 16: a 2.6-fold greater mean GRASSP Total Score and 3.7-fold greater GRASSP Quantitative Prehension versus placebo, higher patient-reported global improvement (75% vs 33%), and gains in bladder control and reduced spasticity. The FDA confirmed multiple regulatory pathways and an End-of-Phase 2 meeting expected in early 2026. On Nov 19, 2025, the company completed a US$10.05M private placement. Cash and investments were $11.4M at Sept 30, 2025.

NervGen (OTCQB:NGENF) reported expanded 16-week CONNECT SCI data showing durable, post-treatment improvements in function, independence, and quality of life in people with chronic spinal cord injury.

Key findings: NVG-291 participants (n=20 trial; avg. 3.5 years post-injury) had a 2.6-fold greater mean GRASSP total score improvement and 3.7-fold greater GRASSP quantitative prehension improvement versus placebo at Week 16; participant interviews up to 364 days reported sustained benefits including bladder control and reduced spasticity.

Neurophysiology: significant reductions in hyperactive reticulospinal signaling (leg 142%, p=0.0062; hand 48%, p=0.0280) and a correlation with strengthened corticospinal signaling (R=-0.794, p=0.006). FDA Type C meeting confirmed multiple regulatory pathways; an End-of-Phase 2 meeting is anticipated in early 2026.

NervGen (OTCQB:NGENF) announced a non-brokered private placement to raise up to US$10.05 million via issuance of up to 4,785,715 units at US$2.10 per unit. Each Unit includes one common share and one-half warrant; each whole warrant is exercisable at US$2.65 for 36 months.

Proceeds are intended to advance the company’s clinical development of NVG-291 and support an anticipated Nasdaq listing. Related parties, including officers and directors, are expected to participate. Closing is subject to TSXV approval and is expected on or about November 19, 2025. Securities will be subject to a four-month-plus-one-day hold.

NervGen Pharma (OTCQB: NGENF) announced groundbreaking Phase 1b/2a topline results for NVG-291 in chronic spinal cord injury treatment. The study demonstrated unprecedented improvements in corticospinal connectivity and functional gains, marking a historic breakthrough in SCI treatment.

Key findings include a 10.2-fold improvement in hand connectivity versus placebo and significant functional improvements in hand use. The treatment was generally safe and well-tolerated. The company reported $15.7 million in cash and investments as of June 30, 2025, with a net loss of $9.1 million for Q2 2025.

Additionally, positive preclinical results showed NVG-291-R's efficacy in treating traumatic hearing loss and peripheral nerve injury in U.S. Department of Defense sponsored studies. The company is now pursuing expedited FDA approval pathways for NVG-291.

NervGen Pharma (OTCQB: NGENF) announced positive preclinical results from two Department of Defense sponsored studies evaluating NVG-291-R, the rodent variant of their lead candidate NVG-291. The studies demonstrated significant therapeutic potential in blast-induced sensorineural hearing loss and peripheral nerve injury models.

In the hearing loss study, daily NVG-291-R treatment showed statistically significant improvements in hearing thresholds across all frequencies by Day 30. For peripheral nerve injury, the treatment led to significant improvements in neuromuscular function and axonal regrowth, with functional gains observed as early as 4 weeks post-injury.

These findings build upon recent successful results from the CONNECT SCI Study, where NVG-291 demonstrated meaningful functional improvements in chronic spinal cord injury patients, reinforcing the drug's broad therapeutic potential across multiple neurological conditions.

NervGen Pharma (OTCQB: NGENF) announced a significant leadership change as President and CEO Mike Kelly steps down, with Board Chairman Dr. Adam Rogers appointed as Interim CEO. The transition follows the company's successful completion of landmark positive results from the chronic cohort of the CONNECT SCI study for their lead candidate NVG-291.

Under Kelly's leadership, NervGen achieved the strongest efficacy signal observed to date in spinal cord injury treatment through their CONNECT SCI study. The company is now preparing to advance discussions with regulators and the SCI community regarding NVG-291's development, which represents a potential best-in-class therapy for spinal cord injury and other nervous system disorders.

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neurological treatments, has provided updates on its ATM Program and stock options. Under the ATM Program, the company sold 385,200 common shares at $2.95 per share during Q2 2025, generating gross proceeds of $1.13 million and net proceeds of $1.11 million after fees.

Additionally, NervGen granted 200,000 stock options to a director, exercisable at $3.55 per share for five years, with quarterly vesting over one year.

NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neurological treatments, announced key leadership changes to its Board of Directors. Dr. Adam Rogers, representing the company's largest shareholder, has been unanimously appointed as the new Board Chair, succeeding Glenn Ives who resigned after four years of service.

The leadership transition comes at a strategic time following positive topline results from the chronic cohort of the Phase 1b/2a CONNECT SCI Study for NVG-291, the company's neuroreparative therapy candidate. Dr. Rogers, who previously served as NervGen's interim president, brings significant expertise as a board-certified physician and biotech entrepreneur, having co-founded Hemera Biosciences and developed HMR59, now in clinical trials as JNJ-1887.